MX342385B - Inhibidores de la ruta del complemento que se unen a c5 y c5a sin evitar la formación de c5b. - Google Patents
Inhibidores de la ruta del complemento que se unen a c5 y c5a sin evitar la formación de c5b.Info
- Publication number
- MX342385B MX342385B MX2015001193A MX2015001193A MX342385B MX 342385 B MX342385 B MX 342385B MX 2015001193 A MX2015001193 A MX 2015001193A MX 2015001193 A MX2015001193 A MX 2015001193A MX 342385 B MX342385 B MX 342385B
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- formation
- preventing
- complement pathway
- pathway inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
La presente invención se refiere a un ácido nucléico aislado que encoda un anticuerpo o un fragmento de unión a antígeno del mismo, en donde el anticuerpo o el fragmento de unión a antígeno del mismo, se une a C5 humano y C5a, y en donde el anticuerpo es una forma quimérica, desinmunizada o humanizada del anticuerpo monoclonal 137-26 producido a partir del hibridoma depositado en la ATCC y designado Pta-3650.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31313701P | 2001-08-17 | 2001-08-17 | |
PCT/US2002/026074 WO2003015819A1 (en) | 2001-08-17 | 2002-08-17 | Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b |
Publications (1)
Publication Number | Publication Date |
---|---|
MX342385B true MX342385B (es) | 2016-09-27 |
Family
ID=23214536
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015001193A MX342385B (es) | 2001-08-17 | 2002-08-17 | Inhibidores de la ruta del complemento que se unen a c5 y c5a sin evitar la formación de c5b. |
MXPA04001301A MXPA04001301A (es) | 2001-08-17 | 2002-08-17 | Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04001301A MXPA04001301A (es) | 2001-08-17 | 2002-08-17 | Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b. |
Country Status (14)
Country | Link |
---|---|
US (6) | US7432356B2 (es) |
EP (1) | EP1425042B2 (es) |
JP (2) | JP4958387B2 (es) |
CN (2) | CN100391537C (es) |
AT (1) | ATE360441T1 (es) |
AU (1) | AU2002331601B2 (es) |
BR (1) | BRPI0211953B8 (es) |
CA (1) | CA2457461C (es) |
DE (1) | DE60219801T3 (es) |
ES (1) | ES2283594T5 (es) |
HK (1) | HK1071304A1 (es) |
MX (2) | MX342385B (es) |
PT (1) | PT1425042E (es) |
WO (1) | WO2003015819A1 (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4958387B2 (ja) | 2001-08-17 | 2012-06-20 | ジェネンテック, インコーポレイテッド | C5bの形成を妨害することなくc5及びc5aに結合する補体経路阻害剤 |
EP1569958B1 (en) | 2002-12-02 | 2009-02-18 | Resistentia Pharmaceuticals AB | Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-c5 amino acid segment and a non-self amino acid segment |
AU2004241069B2 (en) | 2003-05-15 | 2010-09-09 | Genentech, Inc. | Methods and compositions for the prevention and treatment of sepsis |
DK1755674T3 (en) | 2004-05-14 | 2015-02-09 | Alexion Pharma Inc | PROLONGED SURVIVAL OF A allograft by inhibiting complement activity |
US20080076138A1 (en) | 2005-03-02 | 2008-03-27 | Astellas Pharma Inc. | Novel Pd Marker for Histone Deacetylase Inhibitor |
CN101193654A (zh) * | 2005-06-14 | 2008-06-04 | 赛托斯生物技术公司 | 抗原偶联物及其用途 |
US20070292421A1 (en) * | 2005-07-28 | 2007-12-20 | Feinberg Bruce B | Method for treating preeclampsia |
KR20180002911A (ko) * | 2005-11-04 | 2018-01-08 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
PL1988882T3 (pl) | 2006-03-02 | 2015-04-30 | Alexion Pharma Inc | Wydłużanie przeżycia alloprzeszczepu poprzez inhibowanie aktywności dopełniacza |
DK2359834T5 (en) | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
ES2568436T3 (es) | 2006-03-31 | 2016-04-29 | Chugai Seiyaku Kabushiki Kaisha | Procedimiento para controlar la farmacocinética en sangre de anticuerpos |
ZA200900954B (en) * | 2006-08-22 | 2010-05-26 | G2 Inflammation Pty Ltd | Ant-C5aR antibodies with improved properties |
PL2061810T3 (pl) | 2006-09-05 | 2015-05-29 | Alexion Pharma Inc | Sposoby i kompozycje do leczenia neuropatii zależnych od przeciwciał |
KR20160092061A (ko) * | 2006-11-02 | 2016-08-03 | 제넨테크, 인크. | 인간화 항-d 인자 항체 |
EP3689912A1 (en) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
EP4238993A3 (en) | 2008-04-11 | 2023-11-29 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
WO2010075257A1 (en) | 2008-12-22 | 2010-07-01 | Chemocentryx, Inc. | C5ar antagonists |
EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
SG185383A1 (en) | 2010-04-30 | 2012-12-28 | Alexion Pharma Inc | Anti-c5a antibodies and methods for using the antibodies |
PL2585064T3 (pl) | 2010-06-24 | 2017-09-29 | Chemocentryx, Inc. | Antagoniści C5AR |
SG190727A1 (en) | 2010-11-30 | 2013-07-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
EP2468295A1 (en) | 2010-12-21 | 2012-06-27 | Affiris AG | Vaccines based on peptides of the complement protein C5a |
DK3798230T3 (en) | 2011-06-06 | 2022-10-31 | Novo Nordisk As | Terapeutiske antistoffer |
WO2013126006A1 (en) * | 2012-02-20 | 2013-08-29 | Swedish Orphan Biovitrum Ab (Publ) | Polypeptides binding to human complement c5 |
US9133269B2 (en) | 2012-08-24 | 2015-09-15 | Anaptysbio, Inc. | Humanized antibodies directed against complement protein C5 |
CN105392803B (zh) * | 2013-05-08 | 2019-12-06 | 诺和诺德股份有限公司 | C5aR拮抗剂的用途 |
US20140335546A1 (en) * | 2013-05-10 | 2014-11-13 | G J Carroll Pty Ltd | Devices and Methods for Determining the Risk of Developing a Serious Infection |
CN107318267B (zh) | 2013-08-12 | 2021-08-17 | 豪夫迈·罗氏有限公司 | 用于治疗补体相关的病症的组合物和方法 |
TR201911279T4 (tr) | 2013-08-28 | 2019-08-21 | Affibody Ab | Mutasyona uğramış bir yapı iskelesine sahip polipeptidlerin bağlanması. |
WO2015028558A1 (en) | 2013-08-28 | 2015-03-05 | Swedish Orphan Biovitrum Ab (Publ) | Stable polypeptides binding to human complement c5 |
NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
US10227397B2 (en) * | 2014-03-20 | 2019-03-12 | Inflarx Gmbh | Inhibitors of C5a for the treatment of viral pneumonia |
BR112016025312A2 (pt) | 2014-05-01 | 2017-10-17 | Genentech Inc | variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem |
CN113121415A (zh) | 2014-09-29 | 2021-07-16 | 凯莫森特里克斯股份有限公司 | 制备C5aR拮抗剂的方法和中间体 |
SG11201607165YA (en) | 2014-12-19 | 2016-09-29 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
CN107428823B (zh) | 2015-01-22 | 2021-10-26 | 中外制药株式会社 | 两种以上抗-c5抗体的组合与使用方法 |
TW201718014A (zh) | 2015-10-12 | 2017-06-01 | 諾華公司 | C5抑制劑於移植相關微血管病之用途 |
JP2018534930A (ja) | 2015-10-30 | 2018-11-29 | ジェネンテック, インコーポレイテッド | 抗d因子抗体及びコンジュゲート |
CN108472382A (zh) | 2015-10-30 | 2018-08-31 | 豪夫迈·罗氏有限公司 | 抗-因子d抗体变体缀合物及其用途 |
EP3390442B1 (en) | 2015-12-18 | 2023-11-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
BR112018014222A2 (pt) | 2016-01-14 | 2018-12-11 | Chemocentryx, Inc. | método de tratamento da glomerulopatia c3 |
UA124734C2 (uk) | 2016-06-14 | 2021-11-10 | Рідженерон Фармасьютікалз, Інк. | Антитіло проти с5 і його застосування |
AU2017285763B2 (en) | 2016-06-17 | 2024-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies and methods of use |
EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8 |
PL3577135T3 (pl) | 2017-01-31 | 2023-12-04 | Chugai Seiyaku Kabushiki Kaisha | Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 |
EA201992091A1 (ru) * | 2017-03-06 | 2020-02-04 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Анти-c5 антитела и их применение |
CA3057146A1 (en) * | 2017-03-23 | 2018-09-27 | The Trustees Of The University Of Pennsylvania | Anti-c5a antibodies and uses thereof |
EP3717916A1 (en) | 2017-11-29 | 2020-10-07 | H. Hoffnabb-La Roche Ag | Target interference suppressed anti-drug antibody assay |
JP2021506241A (ja) | 2017-12-13 | 2021-02-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 抗c5抗体組み合わせ物およびその使用 |
EP3829628B1 (en) | 2018-08-01 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease |
CN114466660A (zh) | 2019-07-31 | 2022-05-10 | 豪夫迈·罗氏有限公司 | 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案 |
CA3144923A1 (en) | 2019-07-31 | 2021-02-04 | Alexandre Antoine Bernard SOSTELLY | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab |
TW202208427A (zh) | 2020-05-06 | 2022-03-01 | 德商因夫萊亞斯有限公司 | 人源化抗c5a抗體 |
JP2023530977A (ja) | 2020-06-16 | 2023-07-20 | エフ. ホフマン-ラ ロシュ アーゲー | 試料中の抗体の遊離抗原を決定するための方法 |
WO2023050233A1 (en) * | 2021-09-29 | 2023-04-06 | The Trustees Of The University Of Pennsylvania | Humanized anti-c5a antibodies and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4686100A (en) * | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
ES2054667T3 (es) * | 1986-04-28 | 1994-08-16 | Cetus Oncology Corp | Anticuerpos monoclonales contra c5a y des-arg74-c5a, su produccion y uso. |
US5260203A (en) † | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5256766A (en) * | 1991-02-19 | 1993-10-26 | The Regents Of The University Of California | Recombinant thrombin receptor and related pharmaceuticals |
CA2186108A1 (en) * | 1994-03-23 | 1995-09-28 | Scott A. Rollins | Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation |
US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5562904A (en) | 1994-07-21 | 1996-10-08 | Alexion Pharmaceuticals, Inc. | Retroviral transduction of cells using soluble complement inhibitors |
AU3729295A (en) * | 1994-09-23 | 1996-04-09 | Alexion Pharmaceuticals, Inc. | Methods for the treatment of inflammatory joint disease |
US5572904A (en) * | 1995-01-05 | 1996-11-12 | Minculescu; Mihai C. | Oscillation lever arm engine |
US6673346B1 (en) * | 1999-08-31 | 2004-01-06 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of sepsis |
JP4958387B2 (ja) | 2001-08-17 | 2012-06-20 | ジェネンテック, インコーポレイテッド | C5bの形成を妨害することなくc5及びc5aに結合する補体経路阻害剤 |
-
2002
- 2002-08-17 JP JP2003520777A patent/JP4958387B2/ja not_active Expired - Lifetime
- 2002-08-17 MX MX2015001193A patent/MX342385B/es unknown
- 2002-08-17 EP EP02768574.2A patent/EP1425042B2/en not_active Expired - Lifetime
- 2002-08-17 DE DE60219801.1T patent/DE60219801T3/de not_active Expired - Lifetime
- 2002-08-17 BR BR0211953-6 patent/BRPI0211953B8/pt not_active IP Right Cessation
- 2002-08-17 MX MXPA04001301A patent/MXPA04001301A/es active IP Right Grant
- 2002-08-17 WO PCT/US2002/026074 patent/WO2003015819A1/en active IP Right Grant
- 2002-08-17 ES ES02768574.2T patent/ES2283594T5/es not_active Expired - Lifetime
- 2002-08-17 CN CNB028161025A patent/CN100391537C/zh not_active Expired - Fee Related
- 2002-08-17 AU AU2002331601A patent/AU2002331601B2/en not_active Ceased
- 2002-08-17 CN CN200810091622.4A patent/CN101387646B/zh not_active Expired - Fee Related
- 2002-08-17 AT AT02768574T patent/ATE360441T1/de active
- 2002-08-17 CA CA2457461A patent/CA2457461C/en not_active Expired - Fee Related
- 2002-08-17 PT PT02768574T patent/PT1425042E/pt unknown
- 2002-08-17 US US10/222,464 patent/US7432356B2/en not_active Expired - Fee Related
-
2005
- 2005-05-19 HK HK05104181.6A patent/HK1071304A1/xx not_active IP Right Cessation
-
2008
- 2008-01-24 US US12/011,058 patent/US8206716B2/en not_active Expired - Fee Related
-
2010
- 2010-09-01 JP JP2010195807A patent/JP5752374B2/ja not_active Expired - Fee Related
-
2012
- 2012-05-29 US US13/482,328 patent/US8372404B2/en not_active Expired - Fee Related
-
2013
- 2013-02-05 US US13/759,687 patent/US8907072B2/en not_active Expired - Fee Related
-
2014
- 2014-11-24 US US14/551,705 patent/US20150086572A1/en not_active Abandoned
-
2016
- 2016-03-22 US US15/076,960 patent/US20160200805A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX342385B (es) | Inhibidores de la ruta del complemento que se unen a c5 y c5a sin evitar la formación de c5b. | |
MX2023001727A (es) | Anticuerpos anti-c5 y usos de los mismos. | |
PH12020552116A1 (en) | Bispecific anti-psma x anti-cd28 antibodies and uses thereof | |
MA32928B1 (fr) | Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer | |
TN2010000210A1 (en) | Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same | |
GEP20104922B (en) | Antibodies to m-csf | |
EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
WO2008140653A3 (en) | Humaneered anti-factor b antibody | |
MY194997A (en) | Anti-ccr7 antibody drug conjugates | |
WO2003016466A3 (en) | ANTI-Aβ ANTIBODIES | |
SG146696A1 (en) | Humanized antibodies against vascular endothelial growth factor | |
PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
CR20210492A (es) | ANTICUERPOS CONTRA AMILOIDES-ß CON PIROGLUTAMATO Y USOS DE ESTOS | |
MX2021012769A (es) | Anticuerpos bloqueadores cd73. | |
MX2022001841A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
AU2024202263A1 (en) | Antibodies to PMEL17 and conjugates thereof | |
DE69426767D1 (de) | Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen. | |
MX2023001776A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
EP1878441A3 (en) | Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b | |
SG148190A1 (en) | Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer | |
MX2022001411A (es) | Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5. | |
MX2021008453A (es) | Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos. | |
DE602005025459D1 (de) | Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum | |
MX2020013894A (es) | Anticuerpos anti-factor xii/xiia y usos de los mismos. | |
IL139571A0 (en) | A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same |